Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
SERA insider Robert Harrison reported multiple sales of Common Stock under Form 144. The filing lists sales on 03/11/2026 (716 shares, 1460.64), 03/09/2026 (3,360 shares, 6585.60), 02/24/2026 (2,000 shares, 4686.00), 01/27/2026 (2,000 shares, 5942.00), and 12/30/2025 (2,000 shares, 6002.60). Several sales are labeled as 10b5-1 Sales. The filing also lists 2,000 Restricted Stock Units dated 02/06/2024.
Sera Prognostics is offering up to $40,000,000 of Class A common stock through an at-the-market sales agreement with William Blair & Company, L.L.C., pursuant to its Form S-3 shelf.
The sales agent may sell shares from time to time at market prices; William Blair may receive commissions up to 3.0%. Shares outstanding were 37,976,764 as of December 31, 2025. The last reported sale price was $2.01 per share on March 17, 2026.
Sera Prognostics, Inc. outlines its business in women’s health diagnostics, centered on its PreTRM blood test, which predicts a pregnant woman’s individualized risk of spontaneous preterm birth between weeks 18 and 20. The report describes extensive validation work through large studies such as PAPR, TREETOP, PREVENT‑PTB, AVERT and PRIME, where test‑and‑treat strategies were associated with lower neonatal morbidity, mortality and shorter neonatal intensive care stays. Sera highlights a commercial collaboration with Elevance Health to secure payment for the PreTRM test and generate additional health‑economic data. The company also details a pipeline of biomarker and predictive analytics products targeting preeclampsia, gestational diabetes, fetal growth restriction, stillbirth, postpartum depression and molecular time‑to‑birth, all built on its proprietary proteomics, bioinformatics platform and large pregnancy biobanks.
Sera Prognostics, Inc. reported fourth quarter and full year 2025 results, highlighting a continued investment phase ahead of broader commercialization of its PreTRM pregnancy test. Fourth quarter 2025 revenue was $10,000, with a net loss of $7.9 million, while full year 2025 revenue was $81,000 and net loss was $31.9 million.
Total 2025 operating expenses were $36.6 million, with research and development of $13.2 million and selling, general and administrative expenses of $23.3 million. The company ended 2025 with $95.8 million in cash, cash equivalents and marketable securities, which it expects to fund operations through key commercial milestones into 2028.
Strategically, Sera emphasized the publication of the pivotal PRIME Study showing the PreTRM test reduced early preterm births and neonatal complications, expanding commercial discussions with payers across 13 U.S. states, progress toward European commercialization, and leadership additions to support its shift from clinical validation to commercial execution.
SERA PROGNOSTICS, INC. reported that Chief Executive Officer Zhenya Lindgardt received new equity awards. She was granted 154,440 shares of Class A Common Stock in the form of restricted stock units at a price of $0.00 per share and a stock option covering 239,442 shares with an exercise price of $1.99 per share.
The RSUs vest over four years, with 1/16 of the original amount vesting in quarterly installments starting on March 10, 2026, as long as she continues to provide services. The stock options vest over four years in 1/48 monthly installments beginning on March 10, 2026. After these grants, she directly holds 892,754 shares of Class A Common Stock.
Sera Prognostics, Inc. reported that its General Counsel, Benjamin Jackson, received new equity compensation awards. He was granted 44,215 shares of Class A common stock, represented by restricted stock units, and 68,550 stock options with an exercise price of $1.9900 per share.
The RSUs vest over four years, with 1/16 of the original grant vesting in quarterly installments starting on March 10, 2026, contingent on continued service. The stock options also vest over four years, with 1/48 of the grant vesting in monthly installments beginning on March 10, 2026. Following these awards, Jackson directly holds 158,935 shares of Class A common stock and 68,550 stock options.
SERA PROGNOSTICS, INC. Chief Medical Officer Tiffany Eul Davis reported receiving new equity awards. She was granted stock options covering 27,034 shares of Class A Common Stock at an exercise price of $1.99 per share, expiring on March 12, 2036.
She also received 17,437 shares of Class A Common Stock in the form of restricted stock units. According to the terms, these RSUs vest over four years in quarterly installments starting on March 10, 2026, while the options vest monthly over four years from the same date, contingent on continued service.
SERA PROGNOSTICS, INC. Chief Commercial Officer Dyaarl Lee Anderson Jr. received new equity awards as part of his compensation. He was granted stock options covering 19,310 shares of Class A common stock at an exercise price of $1.99 per share, expiring on March 12, 2036. He also received 12,455 shares of Class A common stock in the form of restricted stock units. These RSUs vest over four years, with 1/16 of the original amount vesting in quarterly installments starting on March 10, 2026, while the options vest over four years with 1/48 vesting in monthly installments from the same date. Following these awards, his direct Class A common stock holdings total 79,569 shares.
Sera Prognostics, Inc. reported that Chief Financial Officer Austin Aerts received new equity awards consisting of restricted stock units and stock options. The grant includes 44,215 shares of Class A common stock in the form of RSUs and 68,550 stock options with an exercise price of $1.99 per share.
The RSUs vest over four years, with 1/16 of the original amount vesting in quarterly installments starting on March 10, 2026, contingent on continued service. The stock options vest over four years in 1/48 monthly installments starting on March 10, 2026 and expire on March 12, 2036. Following the RSU grant, Aerts directly holds 308,667 shares of Class A common stock.
Sera Prognostics, Inc. Chief Executive Officer Zhenya Lindgardt reported selling a total of 25,612 shares of Class A common stock in two open-market transactions on March 10 and March 11, 2026 at weighted average prices of $1.90 and $2.04 per share.
According to the disclosure, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations from vesting restricted stock units, and are not discretionary trades. After the transactions, Lindgardt directly holds 738,314 shares. The trades were executed as block trades within disclosed price ranges.